JP2024521063A - Tertをコードする組換えウイルスゲノム及びウイルスベクター - Google Patents

Tertをコードする組換えウイルスゲノム及びウイルスベクター Download PDF

Info

Publication number
JP2024521063A
JP2024521063A JP2023570195A JP2023570195A JP2024521063A JP 2024521063 A JP2024521063 A JP 2024521063A JP 2023570195 A JP2023570195 A JP 2023570195A JP 2023570195 A JP2023570195 A JP 2023570195A JP 2024521063 A JP2024521063 A JP 2024521063A
Authority
JP
Japan
Prior art keywords
aav9
seq
promoter
aav
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023570195A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024521063A5 (cg-RX-API-DMAC7.html
Inventor
マリア ブラスコ
パウラ マルティネス
トゥベール マリア ファティマ ボッシュ
センツァーノ ヴェロニカ ヒメネス
マルティネス ミケル ガルシア
ロレンテ エステファニア カサナ
Original Assignee
フンダシオン デル セクトル パブリコ エスタタル セントロ ナショナル デ インベスティガシオネス オンコロジカス カルロス テルセーロ(エフェ.エセ.ペ. セエネイオ)
ウニベルシタ アウトノマ デ バルセロナ
テロメア セラピューティクス エセエレ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フンダシオン デル セクトル パブリコ エスタタル セントロ ナショナル デ インベスティガシオネス オンコロジカス カルロス テルセーロ(エフェ.エセ.ペ. セエネイオ), ウニベルシタ アウトノマ デ バルセロナ, テロメア セラピューティクス エセエレ filed Critical フンダシオン デル セクトル パブリコ エスタタル セントロ ナショナル デ インベスティガシオネス オンコロジカス カルロス テルセーロ(エフェ.エセ.ペ. セエネイオ)
Publication of JP2024521063A publication Critical patent/JP2024521063A/ja
Publication of JP2024521063A5 publication Critical patent/JP2024521063A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023570195A 2021-05-12 2022-05-12 Tertをコードする組換えウイルスゲノム及びウイルスベクター Pending JP2024521063A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21382441.0A EP4089171A1 (en) 2021-05-12 2021-05-12 Recombinant tert-encoding viral genomes and vectors
EP21382441.0 2021-05-12
PCT/EP2022/062990 WO2022238557A1 (en) 2021-05-12 2022-05-12 Recombinant tert-encoding viral genomes and vectors

Publications (2)

Publication Number Publication Date
JP2024521063A true JP2024521063A (ja) 2024-05-28
JP2024521063A5 JP2024521063A5 (cg-RX-API-DMAC7.html) 2025-05-20

Family

ID=75919286

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023570195A Pending JP2024521063A (ja) 2021-05-12 2022-05-12 Tertをコードする組換えウイルスゲノム及びウイルスベクター

Country Status (9)

Country Link
US (2) US20250099618A1 (cg-RX-API-DMAC7.html)
EP (2) EP4089171A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024521063A (cg-RX-API-DMAC7.html)
CN (1) CN117836420A (cg-RX-API-DMAC7.html)
AU (1) AU2022273863A1 (cg-RX-API-DMAC7.html)
CA (1) CA3219795A1 (cg-RX-API-DMAC7.html)
ES (1) ES3073712T3 (cg-RX-API-DMAC7.html)
MX (1) MX2023013385A (cg-RX-API-DMAC7.html)
WO (1) WO2022238557A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12668817B1 (en) * 2025-07-10 2026-06-30 Telomere Therapeutics S.L. Recombinant adeno-associated viral vectors for delivering a therapeutic gene to lungs

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010016352A1 (en) * 1994-05-18 2001-08-23 Robert J. Bohinski Nucleic acid sequences controlling lung cell-specific gene expression
EP2402038A1 (en) * 2010-07-02 2012-01-04 Fundación Centro Nacional De Investigaciones Oncológicas Carlos III Telomerase reverse transcriptase for protection against ageing
US20140088175A1 (en) * 2004-09-08 2014-03-27 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Transduction of cells by adeno-associated virus vectors
WO2016020345A1 (en) * 2014-08-08 2016-02-11 F. Hoffmann-La Roche Ag Telomerase reverse transcriptase-based therapies

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US6268213B1 (en) 1992-06-03 2001-07-31 Richard Jude Samulski Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy
US5869305A (en) 1992-12-04 1999-02-09 The University Of Pittsburgh Recombinant viral vector system
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US5741683A (en) 1995-06-07 1998-04-21 The Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US5952221A (en) 1996-03-06 1999-09-14 Avigen, Inc. Adeno-associated virus vectors comprising a first and second nucleic acid sequence
EP1007637B1 (en) 1997-04-14 2004-06-30 Cell Genesys, Inc. Methods for increasing the efficiency of recombinant aav product
US6207455B1 (en) 1997-05-01 2001-03-27 Lung-Ji Chang Lentiviral vectors
CN1247788C (zh) 1997-05-13 2006-03-29 北卡罗来纳-查佩尔山大学 基于慢病毒的基因转移载体
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6218181B1 (en) 1998-03-18 2001-04-17 The Salk Institute For Biological Studies Retroviral packaging cell line
US6146874A (en) 1998-05-27 2000-11-14 University Of Florida Method of preparing recombinant adeno-associated virus compositions
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
DE19909769A1 (de) 1999-03-05 2000-09-07 Bundesrepublik Deutschland Let Von SIVagm abgeleitete lentivirale Vektoren, Verfahren zu ihrer Herstellung und ihre Verwendung zur Genübertragung in Säugerzellen
AU6814901A (en) 2000-06-01 2001-12-11 Univ North Carolina Methods and compounds for controlled release of recombinant parvovirus vectors
AU2003274397A1 (en) 2002-06-05 2003-12-22 University Of Florida Production of pseudotyped recombinant aav virions
US9453209B2 (en) * 2012-12-27 2016-09-27 Sierra Sciences, Llc Enhancing health in mammals using telomerase reverse transcriptase gene therapy
ES2936383T3 (es) 2014-08-08 2023-03-16 Fundacion Del Sector Publico Estatal Centro Nac De Investigaciones Oncologicas Carlos Iii F S P Cnio Terapias basadas en transcriptasa inversa de la telomerasa para el tratamiento de afecciones asociadas con el infarto de miocardio

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010016352A1 (en) * 1994-05-18 2001-08-23 Robert J. Bohinski Nucleic acid sequences controlling lung cell-specific gene expression
US20140088175A1 (en) * 2004-09-08 2014-03-27 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Transduction of cells by adeno-associated virus vectors
EP2402038A1 (en) * 2010-07-02 2012-01-04 Fundación Centro Nacional De Investigaciones Oncológicas Carlos III Telomerase reverse transcriptase for protection against ageing
WO2016020345A1 (en) * 2014-08-08 2016-02-11 F. Hoffmann-La Roche Ag Telomerase reverse transcriptase-based therapies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JUAN MANUEL POVEDANO; ET AL: "THERAPEUTIC EFFECTS OF TELOMERASE IN MICE WITH PULMONARY FIBROSIS INDUCED BY DAMAGE TO 以下備考", ELIFE, vol. 7, JPN5025010778, 30 January 2018 (2018-01-30), pages 31299 - 1, ISSN: 0005875103 *

Also Published As

Publication number Publication date
US20260115322A1 (en) 2026-04-30
WO2022238557A1 (en) 2022-11-17
ES3073712T3 (en) 2026-07-14
EP4337780A1 (en) 2024-03-20
MX2023013385A (es) 2024-02-06
AU2022273863A1 (en) 2023-12-07
US20250099618A1 (en) 2025-03-27
EP4337780B1 (en) 2026-04-01
CN117836420A (zh) 2024-04-05
EP4089171A1 (en) 2022-11-16
EP4337780C0 (en) 2026-04-01
CA3219795A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
US11613766B2 (en) Adeno-associated virus variant capsids and methods of use thereof
US11905312B2 (en) Methods and compositions for gene transfer across the vasculature
WO2023060269A1 (en) Recombinant adeno-associated viruses for targeted delivery
CN121127599A (zh) 具有心肌和骨骼肌特异性靶向基序的重组aav突变载体及含有其的组合物
US20260115322A1 (en) Recombinant tert-encoding viral genomes and vectors
WO2024069144A1 (en) Rna editing vector
KR20230082613A (ko) Cns 또는 근육 전달을 위한 재조합 아데노-연관 바이러스
US20250163469A1 (en) Adeno-associated virus variant capsids and methods of use thereof
HK40109651A (en) Recombinant tert-encoding viral genomes and vectors
HK40119094A (en) Adeno-associated virus variant capsids and methods of use thereof
WO2025217117A1 (en) Compositions with cardiac and skeletal muscle-specific targeting motifs and uses thereof
JP2026507523A (ja) 遺伝子療法のためのbcl2関連アタノゲン3(bag3)をコードする核酸
KR20250096825A (ko) 목적 유전자용 발현 카세트 및 이의 용도
HK40104471A (en) Expression cassettes for target genes and their applications
HK40036161A (zh) 腺相关病毒变异衣壳和其使用方法
WO2020187272A1 (zh) 一种用于基因治疗的融合蛋白及其应用
HK40036161B (en) Adeno-associated virus variant capsids and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240110

A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20240110

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20240221

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20240110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240221

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20240410

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240410

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250509

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250509

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260602